← Busulphan

Patient counseling sheet

Print-ready and generated without storing patient details.

AfyaIndex · counseling handout

Busulphan

Therapeutic agent (verify pharmacological class)

Prepared 19 Sep 2026

What it is used for

Chronic myelogenous leukemia [CML]; myeloproliferative disorders like severe thrombocytosis and polycythemia vera; an adjunct in the treatment of myelofibrosis; a component of pretransplant conditioning regimens in patients undergoing bone marrow transplantation for non-malignant diseases.

Warnings

It must be used only under constant supervision by physicians experienced in therapy with cytotoxic agents due to its low therapeutic index; increased incidence of infections; increased incidence of hemorrhagic complications; blood counts should be performed at least once a week. C

Possible side effects

Its major side effect is haematological toxicity, which include severe leukopenia, anaemia, and severe thrombocytopenia; hyperuricaemia due to increased catabolism; uric acid nephropathy; renal stones; acute renal failure.

Storage

Store as labelled. Keep out of reach of children.

No reviewed patient-education article is available. The fields shown are from the currently verified medicine record and unavailable fields are not inferred.

AfyaIndex dataset coverage